TheraRadar
← Back
Data updated: Jun 28, 2026

BIOVAIL LABS INTL

Specialty

BIOVAIL LABS INTL is a specialty pharmaceutical company focused on Cardiovascular.

1988
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

BIOVAIL LABS INTL's Key Drugs

BIOVAIL LABS INTL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

BIOVAIL LABS INTL's Recent FDA Approvals

New NDA/BLA approvals for BIOVAIL LABS INTL over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BIOVAIL LABS INTL's Therapeutic Areas

BIOVAIL LABS INTL's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 100%
1 drugs

BIOVAIL LABS INTL's Top Competitors

BIOVAIL LABS INTL's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

BIOVAIL LABS INTL Pipeline Snapshot

Active clinical trials for BIOVAIL LABS INTL across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling